Mineralys Therapeutics Aktie News

New York City-based Findell Capital Management added 250,000 shares of MLYS, valued at $9.5 million, in the third quarter. The purchase marked a new position for Findell, which reported holding no shares of MLYS in the previous quarter.

RADNOR, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on November 24, 2025, the Compensatio...

Mineralys Therapeutics, Inc. ( MLYS ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Jon Congleton - President, CEO & Director Adam Levy - CFO & Secretary David Rodman - Chief Medical Officer Eric Warren Conference Call Participants Daniel Ferry - Lifesci Advisors, LLC Umer Raffat - Evercore ISI Institutional Equities, Research Division Jin Law - Goldman Sachs Group, I...

– Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 – – Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.

– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session - RADNOR, Pa., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company developing therapies to target hypertension and related comorbidities such as chronic kidney disease (CKD)...

~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~ ~ Phase 3 data of the Launch-HTN Trial of lorundrostat to be included in “Best of Journal of the American Medical Association and the New England Journal of Medicine” presentation~ RADNOR, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Minera...

Mineralys Therapeutics, Inc. advances lorundrostat, its lead aldosterone inhibitor, for uncontrolled and resistant hypertension with pivotal Phase 3 successes. Mineralys achieved positive Phase 2 results in CKD patients with hypertension, supporting NDA submission and expanding lorundrostat's potential patient base. A pre-NDA meeting with the FDA is set for Q4 2025, with additional Phase 2 data...

~ Topline results from the EXPLORE-OSA trial are anticipated in 1Q 2026 ~ RADNOR, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregula...